menu
    • menu
    [{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"CD38-GEAR-NK","moa":"||CD-38","graph1":"Oncology","graph2":"Preclinical","graph3":"VyGen-Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VyGen-Bio \/ Coeptis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"VyGen-Bio \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Partnership","leadProduct":"CD38-GEAR-NK","moa":"CD-38","graph1":"Oncology","graph2":"Preclinical","graph3":"VyGen-Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VyGen-Bio \/ Coeptis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"VyGen-Bio \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"VyGen-Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VyGen-Bio \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"VyGen-Bio \/ Coeptis Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by VyGen-Bio

    Menu

    VyGen-Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VyGen-Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            VyGen-Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD38-GEAR-NK,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Coeptis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Coeptis Secures Worldwide Rights to Next-Generation GEAR Cell Therapy Platform

                            Details : Coeptis has licensed exclusive worldwide development and commercialization rights to the GEAR™ (Gene Edited Antibody Resistant) cell therapy platform, to initially evaluate CD38-GEAR-NK.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            March 11, 2025

                            Lead Product(s) : CD38-GEAR-NK,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Coeptis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VyGen-Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            VyGen-Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD38-GEAR-NK

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Coeptis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Partners with VyGen-Bio, Inc. to Co-develop Two Assets Designed to Improve the Treatment ...

                            Details : Securing the ownership in the co-development assets for CD38-GEAR-NK and CD38 Diagnostic from VyGen-Bio is a critical step in the growth of Coeptis Therapeutics and in the development of these potentially groundbreaking technologies targeting CD38-relate...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            August 19, 2021

                            Lead Product(s) : CD38-GEAR-NK

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Coeptis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VyGen-Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            VyGen-Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Coeptis Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Coeptis Pharmaceuticals Enters into Exclusive Option Agreements with VyGen-Bio

                            Details : The first option agreement involves co-development rights to CD38-GEAR-NK, an autologous NK cell-based therapeutic, gene-edited to enable combination therapy with anti-CD38 mAbs. The second option agreement involves co-development rights to CD38-Diagnost...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 18, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Coeptis Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth